Company research / MRK

Merck & Co., Inc. (MRK)

CIK 0000310158 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated NJ
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Merck & Co., Inc. reported revenue of $65.01B. Revenue grew 1.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $66.57B.

Key ratios (year ended 2025-12-31)

74.8%
Gross margin (computed)
28.1%
Net margin
34.7%
Return on year-end equity
1.3%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-13

Headquarters locality: Rahway · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$66.57B$65.01B$64.17B$60.12B$59.28B$48.70B$41.52B$39.12B$42.29B$40.12B$39.81B
Cost of Revenue$18.00B$16.38B$15.19B$16.13B$17.41B$13.63B$13.62B$12.02B$13.51B$12.91B$14.03B
Gross Profit (computed)$48.57B$48.63B$48.98B$43.99B$41.87B$35.08B$27.90B$27.11B$28.79B$27.21B$25.78B
R&D Expense$30.45B$15.79B$17.94B$30.53B$13.55B$12.24B$13.40B$9.72B$9.75B$10.34B$10.26B
Depreciation & Amortizationn/an/an/an/an/an/an/a$3.65B$4.52B$4.68B$5.47B
Net Income$3.17B$18.25B$17.12B$365.00M$14.52B$13.05B$7.07B$9.84B$6.22B$2.39B$3.92B
EPS (Diluted)n/a$7.28$6.74$0.14$5.71$5.14$2.78$3.81$2.32$0.87$1.41
Total Assets$129.80B$136.87B$117.11B$106.67B$109.16B$105.69B$91.59B$84.40B$82.64B$87.87B$95.38B
Shareholders' Equity$41.98B$52.66B$46.37B$37.63B$46.06B$38.26B$25.40B$26.00B$26.88B$34.57B$40.31B
Cash & Equivalents$6.85B$14.56B$13.24B$6.84B$12.69B$8.10B$8.05B$9.68B$7.96B$6.09B$6.51B
Operating Cash Flow$19.97B$16.47B$21.47B$13.01B$19.09Bn/a$10.25B$13.44B$10.92B$6.45B$10.38B
Capital Expenditures$3.90B$4.11B$3.37B$3.86B$4.39B$4.45B$4.43B$3.37B$2.62B$1.89B$1.61B
Free Cash Flow$16.06B$12.36B$18.10B$9.14B$14.71Bn/a$5.82B$10.07B$8.31B$4.56B$8.76B
Share Repurchases$4.21B$5.08B$1.31B$1.35B$0$840.00M$1.28B$4.78B$9.09B$4.01B$3.43B
Dividends Paid$8.30B$8.18B$7.84B$7.45B$7.01B$6.61B$6.21B$5.70B$5.17B$5.17B$5.12B
Dividends Per Sharen/a$3.28$3.12$2.96$2.80$2.64$2.48$2.26$1.99$1.89$1.85
Weighted Average Diluted Sharesn/a2.51B2.54B2.55B2.54B2.54B2.54B2.58B2.68B2.75B2.79B
EPS (Basic)n/a$7.30$6.76$0.14$5.73$5.16$2.79$3.84$2.34$0.88$1.42

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView